Clairity Breast Cancer AI: New FDA-Authorized System for Risk Prediction

Boston-based AI startup Clairity has unveiled its FDA-authorized AI system. This significant development targets breast cancer risk prediction. The innovative Clairity breast cancer AI platform aims to improve early detection efforts. This represents a notable advancement in medical AI technology.

What Happened

Clairity announced the launch and recent authorization of its predictive AI system. The Food and Drug Administration (FDA) has authorized this new platform. Patient assessments commenced this month. These began at a Beth Israel Deaconess Medical Center clinic in Chestnut Hill.

Details From Sources

The Clairity breast cancer AI system functions by analyzing typical mammogram images. It pinpoints women at a high risk of developing breast cancer. This system identifies high-risk individuals with much greater accuracy than traditional methods. Traditional methods often rely on family histories and questionnaires (RSNA). Identifying these women enables doctors to suggest habit changes. This includes avoiding alcohol or prescribing preventive medicines like Tamoxifen. Clairity secured $43 million from investors last year (Businesswire). The AI program was trained with over 400,000 actual mammograms. Each patient was tracked for five years following their mammogram. The training data included diverse patients. These patients were from different zip codes, races, and ethnicities. They also had varied physical breast characteristics. This AI, utilizing a deep convolutional neural network, was tested. It was tested against 77,000 mammograms and outperformed traditional risk assessment methods.

Why This Matters

Improved risk assessment holds significant potential impact. It can identify women missed by traditional methods. A more accurate system might encourage preventative treatments. This is crucial given medications’ serious side effects. The system could work better for all people. This addresses disparities, noted Elizabeth Mittendorf. Mittendorf is chief of breast surgery at Beth Israel Deaconess. Other risk calculators were developed and validated in white, European women. The Clairity system may be useful. It can assess mammograms from patients as young as 30 years old.

Background Context

Dr. Connie Lehman created this AI program. She spent two decades as a radiologist. This was at Massachusetts General Hospital. She screened for breast cancer and wrote many scientific papers. Her idea for using AI emerged from observations. She saw increasing cancer incidence in younger women. Also, some patients lacked a family history of the disease.

Industry Reactions

Healthcare startup investor Michael Greeley shared his observations. Greeley is general partner at Flare Capital in Boston. He sees potential for more startups. These companies combine AI and medical data in the region. Greeley stated, “a company like Clairity underscores the power of our community as the health care and technology sectors continue to collaborate.” Flare Capital did not invest in Clairity. Clairity’s most recent backing came from Geneva-based ACE Global Equity. Texas-headquartered Santé Ventures also invested, among others. Greeley noted positively that investors from other parts of the country are investing in Boston.

Related Data or Statistics

Breast cancer is the leading cause of cancer death among women. It kills about 42,000 people in the U.S. annually. Survival rates have improved dramatically since the 1970s. However, no significant improvement occurred in the past 20 years. A racial gap exists in survival rates. Early detection is higher in white women. It is lower in Black and non-white Hispanic women.

Future Implications (SPECULATIVE)

Dr. Lehman envisions applying AI to predict other diseases. This could use mammograms and other images. Examples include chest x-rays. She believes looking back in 10 years, it will seem “crazy.” Predictive information was hidden in stored images.

Conclusion

Clairity’s FDA-authorized AI system marks a key achievement. This system has the potential to transform breast cancer risk prediction. It also aims to enhance early detection capabilities.

FAQ

• What is Clairity’s new AI system designed to do?

  Clairity’s FDA-authorized AI system is designed to predict the risk of breast cancer using typical mammogram images.

• How does Clairity’s AI system improve breast cancer risk prediction compared to traditional methods?

  The system pinpoints women at high risk with much greater accuracy than traditional methods, which typically rely on family histories and questionnaires.

• Who developed the Clairity AI system?

  The AI program was created by Dr. Connie Lehman, who has over two decades of experience as a radiologist.

• Has Clairity’s AI system received regulatory approval?

  Yes, Clairity’s predictive AI system has received authorization from the Food and Drug Administration (FDA).

• How was the Clairity AI system trained?

  The AI program was trained using over 400,000 actual mammograms, with patients tracked for five years. The training set included diverse individuals from different zip codes, races, ethnicities, and physical breast characteristics.